Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 125.00 | |
5 mg | In stock | $ 313.00 | |
10 mg | In stock | $ 497.00 | |
25 mg | In stock | $ 788.00 | |
50 mg | In stock | $ 1,080.00 | |
100 mg | In stock | $ 1,480.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 345.00 |
Description | ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI). |
In vivo | ABR-238901, given at a dose of 30 mg/kg/day through gavage over a period of 3 weeks, demonstrates reduced angiogenesis and lowered levels of IL6 and IL10 in MDSCs [1]. When ABR-238901 (30 mg/kg/day via gavage) is combined with Bortezomib (0.6 mg/kg via subcutaneous injection, twice a week), it leads to a decreased tumor burden compared to using either agent alone [1]. In C57BL/6NRJ mice with myocardial ischemia resulting from permanent coronary artery ligation, ABR-238901 administered at a dose of 30 mg/kg via intraperitoneal injection for the initial 3 days, followed by continuous oral administration daily for 21 days, induces progressive deterioration of cardiac function and accelerates left ventricular remodeling. However, when ABR-238901 is administered during the first 3 days post-myocardial infarction, it limits inflammatory damage and promotes a reparative environment [2]. |
Molecular Weight | 394.63 |
Formula | C11H9BrClN3O4S |
CAS No. | 1638200-22-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 0.1 mg/mL (insoluble), Sonification and heating to 60℃ are recommended.
DMSO: 30.0 mg/mL (76.0 mM), Sonification and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ABR-238901 1638200-22-2 Immunology/Inflammation TLR ABR238901 ABR 238901 inhibitor inhibit